immunotherapy malaria hemorragic fever geovax vaccines zika aids/hiv hbv lassa lasv

GeoVax Labs, Inc. (GOVX-OTC) Reports Vaccine Development Progress

By
1 Minute Read

GeoVax_Logo_Clear_1.jpg

GeoVax Labs announced today that its Chief Scientific Officer, Dr. Farshad Guirakhoo, will deliver a talk during the 12th Vaccine Congress, organized by Elsevier and Vaccine journal, being held September 16-19th, 2018 in Budapest, Hungary. 

Dr. Guirakhoo’s presentation is entitled “Development of Novel, Safe and Efficacious Single-Dose Vaccines; Zika, Ebola and Lassa Fever as Examples” and will be delivered on September 18thGeoVax’s vaccine technology platform integrates its recombinant Modified Vaccinia Ankara (MVA) vector with advanced antigen design (Virus-Like Particle, VLP) and state-of-the-art manufacturing technologies.

The Company's technology is supported with funding from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and is performed at laboratories of the Centers for Disease Control and Prevention, (CDC) in Fort Collins, CO, Institute of Human Virology, University of MD and NIH’s Rocky Mountain Laboratories, which have demonstrated the broad utility of the MVA-VLP platform, especially to deliver single-dose vaccines for emerging infectious diseases such as Zika, Lassa fever and Ebola.

During his talk, Dr. Guirakhoo will present proof-of-concept studies for three independent vaccines against three different viral families. The Company has demonstrated full protection after a single dose using various preclinical lethal challenge models.

In addition to vaccines against emerging infectious diseases, GeoVax is developing prophylactic and therapeutic vaccines for other infectious disease as well as cancer. These include prophylactic and therapeutic vaccines for HIV (already in advanced clinical trials), preventive vaccines for Marburg, Sudan and Malaria, all with major epidemic potential with high human lethality, as well as therapeutic vaccines for chronic Hepatitis B infections and tumor-associated antigen (TAA)-based-cancer vaccines.

For more information on GeoVax, please refer to our most recent Quarterly Update (https://bit.ly/2x4w4t8) dated August 14, 2018, as well as our Executive Informational Overview (EIO), issued on June 15, 2017 and available for download below.

Download GeoVax Report 

 

*******************************************

Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.

*******************************************